$776.2 M

RYTM Mkt cap, 13-Feb-2020
Rhythm Pharmaceuticals Net income (Q3, 2017)-10 M
Rhythm Pharmaceuticals EBIT (Q3, 2017)-8.3 M
Rhythm Pharmaceuticals Cash, 30-Sept-201727.9 M

Rhythm Pharmaceuticals Income Statement

Annual

USDFY, 2015FY, 2016

R&D expense

7.1m19.6m

General and administrative expense

3.4m6.3m

Operating expense total

10.6m25.9m

EBIT

(10.6m)(25.9m)

Interest income

33.0k

Net Income

(11.1m)(25.9m)

Quarterly

USDQ3, 2016Q3, 2017

R&D expense

5.4m6.0m

General and administrative expense

982.0k2.3m

Operating expense total

6.4m8.3m

EBIT

(6.4m)(8.3m)

Interest income

10.0k51.0k

Net Income

(6.4m)(10.0m)

Rhythm Pharmaceuticals Balance Sheet

Annual

USDFY, 2015FY, 2016

Cash

34.9m6.5m

Prepaid Expenses

623.0k638.0k

Current Assets

35.5m11.2m

PP&E

17.0k930.0k

Total Assets

37.3m12.3m

Accounts Payable

1.4m1.9m

Current Liabilities

5.3m4.7m

Total Liabilities

5.3m5.0m

Common Stock

10.0k10.0k

Additional Paid-in Capital

42.7m43.8m

Retained Earnings

(50.7m)(76.5m)

Total Equity

(8.0m)(32.7m)

Financial Leverage

-4.7 x-0.4 x

Quarterly

USDQ2, 2017Q3, 2017

Cash

8.7m27.9m

Prepaid Expenses

722.0k1.6m

Current Assets

18.5m32.0m

PP&E

822.0k845.0k

Total Assets

20.4m34.8m

Accounts Payable

1.3m2.3m

Current Liabilities

4.8m5.5m

Total Liabilities

5.5m5.7m

Common Stock

10.0k2.0k

Additional Paid-in Capital

44.4m47.8m

Retained Earnings

(89.7m)(99.7m)

Total Equity

(45.3m)(51.9m)

Financial Leverage

-0.5 x-0.7 x

Rhythm Pharmaceuticals Cash Flow

Annual

USDFY, 2015FY, 2016

Net Income

(11.1m)(25.9m)

Depreciation and Amortization

144.0k

Accounts Payable

893.0k467.0k

Cash From Operating Activities

(7.0m)(23.2m)

Purchases of PP&E

(17.0k)(1.1m)

Cash From Investing Activities

(17.0k)(5.1m)

Cash From Financing Activities

41.7m

Net Change in Cash

34.7m(28.3m)

Quarterly

USDQ2, 2016Q3, 2016Q2, 2017Q3, 2017

Net Income

(11.1m)(17.5m)(13.2m)(23.2m)

Depreciation and Amortization

33.0k89.0k108.0k163.0k

Accounts Payable

882.0k(335.0k)(602.0k)830.0k

Cash From Operating Activities

(12.6m)(17.0m)(13.2m)(21.6m)

Purchases of PP&E

(986.0k)(1.1m)(78.0k)

Cash From Investing Activities

(6.3m)(5.2m)(5.0m)1.4m

Cash From Financing Activities

20.4m41.5m

Net Change in Cash

(18.9m)(22.3m)2.2m21.4m

Rhythm Pharmaceuticals Ratios

USDY, 2017

Financial Leverage

-0.7 x